Skip to main
MDWD
MDWD logo

MediWound (MDWD) Stock Forecast & Price Target

MediWound (MDWD) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MediWound Ltd reported total revenues of $4.0 million for Q1 2024, slightly below the consensus estimate of $5.08 million. The company experienced a net loss of $0.7 per share, which was marginally worse than the consensus estimated loss of $0.65 per share. Despite these results, MediWound's focus on developing innovative biopharmaceutical products and its existing FDA-approved product, NexoBrid, position it favorably in the market for addressing significant medical needs, supporting a positive long-term outlook for the company's stock.

Bears say

MediWound Ltd has postponed the anticipated launch of its product EscharEx in the U.S. by one year, now expected in the third quarter of 2028, which may hamper revenue growth prospects. The company currently reports no income from discontinued operations, indicating a lack of cash flow generation during this uncertain period. These factors collectively contribute to a negative outlook for the stock, highlighting delays in product development and potential future revenue challenges.

MediWound (MDWD) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MediWound and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MediWound (MDWD) Forecast

Analysts have given MediWound (MDWD) a Strong Buy based on their latest research and market trends.

According to 2 analysts, MediWound (MDWD) has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MediWound (MDWD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.